Drug Information

Drug General Information
Drug ID
D0H7FW
Former ID
DIB002663
Drug Name
YF-476
Synonyms
Sograzepide; FE-999008; Gastrin inhibitor, Ferring; YM-476
Drug Type
Small molecular drug
Indication Stomach ulcer [ICD10:K25-K27] Phase 2 [523439], [543278]
Company
Ferring Pharmaceuticals Inc
Formula
C28H30N6O3
InChI
InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)/t25-/m0/s1
InChIKey
YDZYKNJZCVIKPP-VWLOTQADSA-N
CAS Number
CAS 155488-25-8
PubChem Compound ID
9870520
PubChem Substance ID
14835525, 24161359, 45292781, 47510060, 47731245, 53790335, 80857341, 81078264, 103339635, 103952506, 129782263, 135276343, 135302059, 135651338, 137489175, 165245623, 198944735, 227604158
Target and Pathway
Target(s) Gastrin/cholecystokinin type B receptor Target Info Inhibitor [527273]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gastric acid secretion
PANTHER Pathway CCKR signaling map ST
PathWhiz Pathway Gastric Acid Production
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
Gastrin-CREB signalling pathway via PKC and MAPK
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Secretion of Hydrochloric Acid in Parietal Cells
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 523439ClinicalTrials.gov (NCT01339169) YF476 and Type I Gastric Carcinoids. U.S. National Institutes of Health.
Ref 543278(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 887).
Ref 527273CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.